ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
126.526,27
1,51%
S&P 500
5.099,96
1,02%
US Dollar vs BRL
5,1163
0,00%
Bitcoin
62.881,29
-1,35%
Brent Oil
88,165
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Incyte Corporation (INCY)

  7. Incyte Corporation (INCY) Notícias

INCY Incyte Corporation

51,15
-0,03 (-0,06%)
26 Abr 2024 - Fechado
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Incyte Corporation INCY NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
Upgrade Icon
-0,03 -0,06% 51,15 21:00:00
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
50,99 50,86 51,85 51,68 51,18
mais cotações »

Notícias Recentes

Data Hora Fonte Título
23/04/202419:11BWIncyte annonce l'acquisition d'Escient Pharmaceuticals et de..
23/04/202419:01BWIncyte gibt Übernahme von Escient Pharmaceuticals und dessen..
23/04/202408:00BWIncyte Announces Acquisition of Escient Pharmaceuticals and..
11/04/202409:00BWIncyte to Report First Quarter Financial Results
01/04/202409:30BWIncyte and CMS Announce Collaboration and License Agreement..
29/03/202417:30BWIncyte Reports Inducement Grant Under Nasdaq Listing Rule..
11/03/202409:57BWIncyte annonce de nouvelles données de l’étude de phase 2..
11/03/202407:06BWIncyte présente de nouvelles données de l’étude de phase 2..
11/03/202406:53BWIncyte legt neue brandaktuelle Daten aus Phase-2-Studie zur..
10/03/202417:05BWIncyte Announces New Data from Phase 2 Study Evaluating..
04/03/202416:38BWDe nouvelles données dérivées du portefeuille dermatologique..
04/03/202416:02BWNeue Daten aus dem wachsenden Dermatologieportfolio von..
04/03/202410:00BWNew Data from Incyte’s Growing Dermatology Portfolio to be..
29/02/202412:19BWIncyte Launches The Unseen Journey to Elevate the Hidden..
29/02/202409:30GLOBEKnight Therapeutics Announces Launch of Minjuvi® in Brazil
28/02/202411:11BWIncyte annonce que la Food and Drug Administration des..
28/02/202409:15BWIncyte gibt bekannt, dass die US-Arzneimittelbehörde FDA..
27/02/202418:08BWIncyte Announces U.S. Food and Drug Administration Grants..
15/02/202410:00BWIncyte to Present at Upcoming Investor Conference
13/02/202409:00BWIncyte Reports 2023 Fourth Quarter and Year-End Financial..
06/02/202406:08BWIncyte erhält exklusive weltweite Rechte für die Entwicklung..
05/02/202422:55BWIncyte obtient les droits exclusifs de développement et de..
05/02/202418:46BWIncyte Gains Exclusive Global Development and..
23/01/202410:00BWIncyte to Report Fourth Quarter and Year-End 2023 Financial..
08/01/202410:30BWIncyte Highlights Growth Opportunities and Provides Business..
12/12/202310:00BWIncyte to Present at Upcoming Investor Conferences
11/12/202308:33BWIncyte und Syndax präsentieren bei ASH-Plenarsitzung weitere..
10/12/202319:00BWIncyte and Syndax Present Additional Data from Positive..
02/11/202310:00BWIncyte to Spotlight More Than 40 Hematology and Oncology..
31/10/202308:00BWIncyte Reports 2023 Third Quarter Financial Results and..
27/10/202309:00BWScience Magazine Recognizes Incyte as #2 “Top Employer” of..
19/10/202307:06IHMARKETNEWSKeep An Eye Out: Pre-Market Movers And Analyst..
18/10/202309:00BWIncyte to Present at Upcoming Investor Conferences
16/10/202317:12BWIncyte présentera de nouvelles données issues de son..
16/10/202309:00BWIncyte Announces New Data from across its Oncology Portfolio..
14/10/202313:30BWIncyte annonce de nouvelles données pour le ruxolitinib en..
13/10/202319:19BWIncyte gibt neue Daten für Ruxolitinib-Creme (Opzelura®®) in..
13/10/202311:30BWIncyte Announces New Data for Ruxolitinib Cream (Opzelura®)..
13/10/202309:00BWData From Incyte’s Povorcitinib Clinical Program to Be..
12/10/202315:16BWLes nouvelles données à long terme du programme TRuE-V de..
11/10/202318:21BWNeue Langzeitdaten aus dem Phase 3 TRuE-V Programm von..
11/10/202317:26BWIncyte präsentiert positive 52-Wochen-Daten aus..
11/10/202313:35BWIncyte annonce des données positives à 52 semaines d'une..
11/10/202311:30BWNew Long-Term Data from Incyte Phase 3 TRuE-V Program..
11/10/202310:15BWIncyte and Mandy Moore Partner to Empower People with Atopic..
11/10/202309:15BWIncyte Announces Positive 52-Week Data from Phase 2b Study..
10/10/202317:45GLOBEKnight Therapeutics Announces Regulatory Submission of..
10/10/202309:00BWIncyte to Report Third Quarter Financial Results
29/09/202323:31BWIncyte präsentiert mehrere Studien zu seinem..
29/09/202314:43BWIncyte to Present Multiple Studies from Dermatology..

Seu Histórico Recente

NASDAQ
INCY
Incyte
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados